{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-242518","form_type":"8-K","ticker":"SRZN","cik":"0001824893","company_name":"Surrozen, Inc./DE","filed_at":"2025-10-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.639288+00:00","generated_at":"2026-05-17T03:25:18.005577+00:00","sec_items":["1.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Surrozen's collaboration agreement terminated by TCGFB for convenience, effective Nov 13","bullets":["TCGFB terminated Collaboration Agreement for convenience; no termination penalties incurred by either party.","Agreement provided Surrozen up to $6.0M in payments plus warrant for 3.4M TCGFB shares at $0.0001/share.","Collaboration was for antibody discovery services; TCGFB owned all TGF-β product IP.","TCGFB is affiliated with The Column Group, a >5% holder of Surrozen stock; board member Kutzkey is TCG Managing Partner."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-242518","json":"https://secwatch.observer/filing/0001193125-25-242518.json","markdown":"https://secwatch.observer/filing/0001193125-25-242518.md","text":"https://secwatch.observer/filing/0001193125-25-242518.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1824893/000119312525242518/0001193125-25-242518-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1824893/000119312525242518/srzn-20251014.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T03:25:18.005577+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}